ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.

BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...

Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep ...

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to ...

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 ...

Let's see which of these two names could be best buys. The post Should I buy Fisher & Paykel or ResMed shares? appeared first ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

Shares of ResMed Inc. RMD advanced 1.78% to $223.85 Monday, on what proved to be an all-around favorable trading session for ...

People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea ...